Literature DB >> 9950295

A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

H Onyüksel1, H Ikezaki, M Patel, X P Gao, I Rubinstein.   

Abstract

PURPOSE: To determine whether human vasoactive intestinal peptide (VIP)-poly(ethylene glycol) (PEG)-grafted distearoyl-phosphatidylethanolamine (DSPE) micelles elicit potent and stable vasodilation in vivo.
METHODS: PEG-DSPE micelles were prepared by co-precipitation. VIP was loaded into micelles by incubation at room temperature. Vasoactivity of VIP in SSM was determined by monitoring changes in diameter of resistance arterioles in the in situ hamster cheek pouch using intravital microscopy.
RESULTS: VIP easily undergoes self-assembly into small PEG-DSPE micelles (mean [+/-SEM] size, 18+/-1 nm) in a time-dependent fashion. This generates a potent vasoactive matrix at nanomole concentrations of VIP as manifested by approximately 3-fold potentiation and prolongation of vasodilation relative to that evoked by aqueous VIP alone (p < 0.05). This response is specific and mediated by the L-arginine/nitric oxide (NO) biosynthetic pathway. Micellar VIP dispersion remains vasoactive for at least 14 days after preparation and storage at 4 degrees C.
CONCLUSIONS: A novel, self-associated, small and stable PEG-DSPE micellar formulation of VIP amplifies vasodilation in the in situ peripheral microcirculation in a specific fashion by elaborating NO. An optimized formulation could be considered for certain cardiovascular disorders associated with L-arginine/NO biosynthetic pathway dysfunction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950295     DOI: 10.1023/a:1018847501985

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Nitric oxide synthase in VIP-containing vasodilator nerve fibres in the guinea-pig.

Authors:  W Kummer; A Fischer; P Mundel; B Mayer; B Hoba; B Philippin; U Preissler
Journal:  Neuroreport       Date:  1992-07       Impact factor: 1.837

2.  Identity of a membrane-bound vasoactive intestinal peptide-binding protein with calmodulin.

Authors:  D Stallwood; C H Brugger; B A Baggenstoss; P M Stemmer; H Shiraga; D F Landers; S Paul
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

3.  VIP receptors in mesenteric and coronary arteries: a radioligand binding study.

Authors:  M Huang; O P Rorstad
Journal:  Peptides       Date:  1987 May-Jun       Impact factor: 3.750

4.  Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood.

Authors:  M Yokoyama; T Okano; Y Sakurai; H Ekimoto; C Shibazaki; K Kataoka
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

Review 5.  The L-arginine-nitric oxide pathway.

Authors:  S Moncada; A Higgs
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

6.  Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo.

Authors:  H Suzuki; Y Noda; S Paul; X P Gao; I Rubinstein
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

7.  Lipid-induced conformational changes in glucagon, secretin, and vasoactive intestinal peptide.

Authors:  R M Robinson; E W Blakeney; W L Mattice
Journal:  Biopolymers       Date:  1982-06       Impact factor: 2.505

8.  The interaction of calmodulin with amphiphilic peptides.

Authors:  J A Cox; M Comte; J E Fitton; W F DeGrado
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

9.  Endothelium-dependent and endothelium-independent vasodilatation of the hepatic artery of the rabbit.

Authors:  A L Brizzolara; G Burnstock
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

10.  Role of the enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase.

Authors:  R C Venema; H S Sayegh; J F Arnal; D G Harrison
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  13 in total

1.  Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.

Authors:  Otilia May Yue Koo; Israel Rubinstein; Hayat Onyüksel
Journal:  Pharm Res       Date:  2010-12-04       Impact factor: 4.200

2.  Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media.

Authors:  Lela Vuković; Fatima A Khatib; Stephanie P Drake; Antonett Madriaga; Kenneth S Brandenburg; Petr Král; Hayat Onyuksel
Journal:  J Am Chem Soc       Date:  2011-08-09       Impact factor: 15.419

3.  Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer.

Authors:  Hacer Cesur; Israel Rubinstein; Ashwini Pai; Hayat Onyüksel
Journal:  Nanomedicine       Date:  2008-12-13       Impact factor: 5.307

4.  Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles.

Authors:  Sok Bee Lim; Israel Rubinstein; Hayat Onyüksel
Journal:  Int J Pharm       Date:  2008-01-17       Impact factor: 5.875

5.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

6.  Optimization of Landscape Phage Fusion Protein-Modified Polymeric PEG-PE Micelles for Improved Breast Cancer Cell Targeting.

Authors:  Tao Wang; Valery A Petrenko; Vladimir P Torchilin
Journal:  J Nanomed Nanotechnol       Date:  2012-04-20

7.  Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs.

Authors:  Aparna Krishnadas; Israel Rubinstein; Hayat Onyüksel
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

Review 8.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

Review 9.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

Authors:  Elena Gonzalez-Rey; Per Anderson; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

10.  Micellar nanomedicine of human neuropeptide Y.

Authors:  Antonina Kuzmis; Sok Bee Lim; Esha Desai; Eunjung Jeon; Bao-Shiang Lee; Israel Rubinstein; Hayat Onyüksel
Journal:  Nanomedicine       Date:  2011-01-25       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.